Specialising in RNA formulation, pharmaceutical manufacturing and medical technology, Winkeljann Holding provides strategic consulting to transition your projects from initial concept towards clinical application. We deliver practical, tailored solutions, supporting both start-ups and established companies in their journey. Reach out to us via: benjamin(at)winkeljann-holding.com. Winkeljann Holding UG (haftungsbeschränkt).
Munich , Bavaria , DE
Winkeljann Holding hat dies direkt geteilt
Today is the first day of Pulmonary Hypertension Awareness Month! This month, we’re celebrating how the pulmonary hypertension community “Lives PHearlessly." Visit our #PHAwarenessMonth toolkit for downloadable graphics, informative materials, a customizable press release and more! https://ow.ly/gOLt50Q0QZc #LivePHearlessly
"Extracellular Vesicles (EVs): The Next Frontier in Gene Therapy Delivery.” This review by Riccardo Cecchin et al. illustrates the unique advantages of EVs such as their biocompatibility, non-immunogenic nature, or ability to traverse the blood-brain barrier. The articles further discusses the challenges of scaling up EV production for clinical use, with current research predominantly focused on refining these natural delivery vehicles in laboratory and animal studies. Moreover, the review highlights the potential of EVs to transfer miRNAs between cells, influencing recipient cell functions—a facet promising for therapeutic intervention. 👇 https://lnkd.in/ehiAe2cH #GeneTherapy #ExtracellularVesicles #DrugDelivery